SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001136261-22-000222
Filing Date
2022-05-12
Accepted
2022-05-12 08:31:35
Documents
15
Period of Report
2022-05-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 25868
2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM exh1-1.htm EX-1.1 231329
3 BROWNSTEIN HYATT FARBER SCHRECK, LLP exh5-1.htm EX-5.1 12003
4 GRAPHIC image_001.jpg GRAPHIC 3521
  Complete submission text file 0001136261-22-000222.txt   510919

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE seel-20220512.xsd EX-101.SCH 3033
6 XBRL LABEL FILE seel-20220512_lab.xml EX-101.LAB 34476
7 XBRL PRESENTATION FILE seel-20220512_pre.xml EX-101.PRE 22595
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3596
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22245 | Film No.: 22915843
SIC: 2834 Pharmaceutical Preparations